Clinical trials: Neuron Disease, Motor

Muscular Atrophy, Spinal

Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients

• Completed
• Age: 6 to 50 years
• Phase 2
• Results posted

A two-period, two-treatment, crossover study to evaluate the safety, tolerability and efficacy of amifampridine phosphate in ambulatory patients diagnosed with spinal muscular atrophy (SMA) Type 3.

Trial name

NCT03781479

Testing

Amifampridine Phosphate

Where

Italy

Volunteers

13 people

Sponsor

Catalyst Pharmaceuticals, Inc.